ALZ-801 is primarily investigated for its potential therapeutic applications in neurodegenerative diseases, particularly Alzheimer's disease. It functions as a prodrug of tramiprosate, aiming to stabilize amyloid-beta oligomers and prevent their aggregation into toxic plaques, which are a hallmark of Alzheimer's pathology. By targeting this mechanism, ALZ-801 may help slow cognitive decline and improve memory function in patients. Clinical trials are ongoing to evaluate its efficacy and safety, with a focus on individuals carrying the APOE4 gene, a known risk factor for Alzheimer's. If successful, it could offer a disease-modifying treatment option for this challenging condition.